-

Guardant Health Named to TIME’s List of the Best Inventions of 2024

Shield™, the first FDA-approved, Medicare-reimbursed colorectal cancer screening blood test, named to the Medical Care list

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing lives.

To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as health care, AI, and green energy. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.

“We’re honored to be a part of this prestigious list of leading innovative products that are making a dramatic difference in how we live our lives today,” said AmirAli Talasaz, co-CEO and co-Founder of Guardant Health. “We created Guardant Health with the vision to detect and characterize cancer across the spectrum, and now we are able to do this with colorectal cancer at earlier stages with the launch of Shield. This has the opportunity to transform cancer detection and save millions of lives.”

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including the world's largest computer chip, a humanoid robot joining the workforce, and a bioluminescent houseplant—that are changing how we live, work, play, and think about what’s possible.”

Guardant recently reached several significant milestones, including announcing that it has achieved 500 peer-reviewed publications and more than 500,000 patient tests delivered. Shield was approved by the Food and Drug Administration in July 2024, and reimbursed by Medicare shortly thereafter.

See the full list here: time.com/best-inventions-2024

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn and X (Twitter).

Contacts

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com

More News From Guardant Health, Inc.

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present a total of 14 abstracts with its research collaborators from multiple studies demonstrating the value of its tissue-free liquid biopsy tests at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025. Oral presentations will highlight results generated with Guardant Reveal, the company’s tissue-free test for detecting minimal residual disease (MRD...

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the public launch of the Single Namespace Working Group (SNS), a 34-member, cross-industry consortium which has drafted the first open standard for exabyte-scale data interoperability. Managing exabyte-scale data across different storage providers is often disruptive, time-consuming, and ultimately costly due to progressively larger data sets needing faster solutions. SN...

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal tracks more than 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient’s blood to predict outcomes sooner than imaging without the need for a tissue sample. Building on...
Back to Newsroom